{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:22:09Z","timestamp":1783092129655,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00702-025-03094-9","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:14:00Z","timestamp":1768220040000},"page":"945-948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The mouse diaphragm assay in botulinum toxin therapy"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4234-5635","authenticated-orcid":false,"given":"Pawel","family":"Tacik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"3094_CR1","first-page":"315","volume":"38","author":"S Adler","year":"2010","unstructured":"Adler S, Bicker G, Bigalke H, Bishop C, Bl\u00fcmel J, Dressler D, Fitzgerald J, Gericke C, Gessler F, Grune B, Hansper M, Heuschen H, Kegel B, Liebsch M, Luch A, Milne C, Pickett A, Ratsch H, Ruhdel I, Sesardic D, Spielmann H, Stephens M, Stiens G, Thornton PD, Th\u00fcrmer R, Vey M (2010) Current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin (BoNT) potency testing: report and recommendations of the ZEBET expert meeting. ATLA 38:315\u2013330","journal-title":"ATLA"},{"key":"3094_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2105\/AJPH.9.6.427","volume":"9","author":"IA Bengtson","year":"1919","unstructured":"Bengtson IA, McCoy GW (1919) Relative value of cultural and inoculation tests for detection of B. tetani. Am J Public Health (NY) 9:427\u2013430","journal-title":"Am J Public Health (NY)"},{"key":"3094_CR3","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.3390\/toxins7124855","volume":"7","author":"H Bigalke","year":"2015","unstructured":"Bigalke H, Rummel A (2015) Botulinum neurotoxins: qualitative and quantitative analysis using the mouse phrenic nerve hemidiaphragm assay (MPN). Toxins 7:4895\u20134905","journal-title":"Toxins"},{"key":"3094_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.14573\/altex.2010.2.114","volume":"27","author":"S Bitz","year":"2010","unstructured":"Bitz S (2010) The botulinum neurotoxin LD50 test - problems and solutions. Altex 27:114\u2013116","journal-title":"Altex"},{"key":"3094_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1476-5381.1946.tb00025.x","volume":"1","author":"E Bulbring","year":"1946","unstructured":"Bulbring E (1946) Observations on the isolated phrenic nerve diaphragm preparation of the rat. Br J Pharmacol Chemother 1:38\u201361","journal-title":"Br J Pharmacol Chemother"},{"key":"3094_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4103\/IJMR.2010_132_05_489","volume":"5","author":"RK Dhaked","year":"2010","unstructured":"Dhaked RK, Singh MK, Singh P, Gupta P (2010) Botulinum toxin: bioweapon and magic drug. Indian J Med Res 5:489\u2013503","journal-title":"Indian J Med Res"},{"key":"3094_CR7","first-page":"219","volume":"364","author":"MB Dorner","year":"2013","unstructured":"Dorner MB, Schulz KM, Kull S, Dorner BG (2013) Complexity of botulinum neurotoxins: challenges for detection technology. Curr Top Microbiol Immuno 364:219\u2013255","journal-title":"Curr Top Microbiol Immuno"},{"key":"3094_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.mib.2012.05.012","volume":"15","author":"D Dressler","year":"2012","unstructured":"Dressler D (2012) Clinical applications of botulinum toxin. Curr Opin Microbiol 15:325\u2013336","journal-title":"Curr Opin Microbiol"},{"key":"3094_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/mds.1238","volume":"17","author":"D Dressler","year":"2002","unstructured":"Dressler D, Bigalke H (2002) Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. Mov Disord 17:170\u2013173","journal-title":"Mov Disord"},{"key":"3094_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000081463","volume":"52","author":"D Dressler","year":"2004","unstructured":"Dressler D, Bigalke H (2004) Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol 52:132\u2013135","journal-title":"Eur Neurol"},{"key":"3094_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/14737175.2017.1262258","volume":"17","author":"D Dressler","year":"2017","unstructured":"Dressler D, Bigalke H (2017) Immunological aspects of botulinum toxin therapy. Expert Rev Neurother 17:487\u2013494","journal-title":"Expert Rev Neurother"},{"key":"3094_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/1531-8257(200009)15:5<973::AID-MDS1031>3.0.CO;2-X","volume":"15","author":"D Dressler","year":"2000","unstructured":"Dressler D, Dirnberger G, Bhatia KP, Irmer A, Quinn NP, Bigalke H, Marsden CD (2000) Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord 15:973\u2013976","journal-title":"Mov Disord"},{"key":"3094_CR13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","volume":"250","author":"D Dressler","year":"2003","unstructured":"Dressler D, Bigalke H, Benecke R (2003) Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 250:967\u2013969","journal-title":"J Neurol"},{"key":"3094_CR14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/mds.20625","volume":"20","author":"D Dressler","year":"2005","unstructured":"Dressler D, Lange M, Bigalke H (2005) Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Mov Disord 20:1617\u20131619","journal-title":"Mov Disord"},{"key":"3094_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00702-011-0719-1","volume":"119","author":"D Dressler","year":"2012","unstructured":"Dressler D, Mander G, Fink K (2012) Measuring the potency labelling of onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae) in an LD50 assay. J Neural Transm 119:13\u201315","journal-title":"J Neural Transm"},{"key":"3094_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2022.153341","volume":"481","author":"D Dressler","year":"2022","unstructured":"Dressler D, Bigalke H, Frevert J (2022) The immunology of botulinum toxin therapy: a brief summary. Toxicologist 481:153341","journal-title":"Toxicologist"},{"key":"3094_CR17","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00415-022-11424-0","volume":"270","author":"D Dressler","year":"2023","unstructured":"Dressler D, Rothwell JC, Bhatia K, Kopp B, Bigalke H, Adib Saberi F (2023) Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations. J Neurol 270:1524\u20131530","journal-title":"J Neurol"},{"issue":"11","key":"3094_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049516","volume":"7","author":"E Fern\u00e1ndez-Salas","year":"2012","unstructured":"Fern\u00e1ndez-Salas E, Wang J, Molina Y, Nelson JB, Jacky BPS, Aoki KR (2012) Botulinum neurotoxin serotype a specific cell-based potency assay to replace the mouse bioassay. PLoS ONE 7(11):e49516","journal-title":"PLoS ONE"},{"key":"3094_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 147:96\u2013102","journal-title":"Exp Neurol"},{"key":"3094_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00500299","volume":"311","author":"E Habermann","year":"1980","unstructured":"Habermann E, Dreyer F, Bigalke H (1980) Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin. Naunyn Schmiedebergs Arch Pharmacol 311:33\u201340","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3094_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/CMR.19.2.298-314.2006","volume":"19","author":"M Lindstrom","year":"2006","unstructured":"Lindstrom M, Korkeala H (2006) Laboratory diagnostics of botulism. Clin Microbiol Rev 19:298\u2013314","journal-title":"Clin Microbiol Rev"},{"key":"3094_CR22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4062\/biomolther.2019.200","volume":"28","author":"MR Nepal","year":"2020","unstructured":"Nepal MR, Jeong TC (2020) Alternative methods for testing botulinum toxin: current status and future perspectives. Biomol Therapeut 28:302\u2013310","journal-title":"Biomol Therapeut"},{"key":"3094_CR23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00702-019-02100-1","volume":"126","author":"L Pan","year":"2019","unstructured":"Pan L, Bigalke H, Kopp B, Jin L, Dressler D (2019) Comparing lanbotulinumtoxinA (Hengli\u00ae) with onabotulinumtoxinA (Botox\u00ae) and incobotulinumtoxinA (Xeomin\u00ae) in the mouse hemidiaphragm assay. J Neural Transm 126:1625\u20131629","journal-title":"J Neural Transm"},{"key":"3094_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1006\/taap.1994.1181","volume":"128","author":"LB Pearce","year":"1994","unstructured":"Pearce LB, Borodic GE, First ER, MacCallum RD (1994) Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 128:69\u201377","journal-title":"Toxicol Appl Pharmacol"},{"key":"3094_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0065-2911(09)05503-9","volume":"55","author":"MW Peck","year":"2009","unstructured":"Peck MW (2009) Biology and genomic analysis of Clostridium botulinum. Adv Microb Physiol 55:183\u2013265","journal-title":"Adv Microb Physiol"},{"key":"3094_CR26","first-page":"257","volume":"364","author":"S Pellett","year":"2013","unstructured":"Pellett S (2013) Progress in cell based assays for botulinum neurotoxin detection. Curr Top Microbiol Immunol 364:257\u2013285","journal-title":"Curr Top Microbiol Immunol"},{"key":"3094_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.toxicon.2009.01.019","volume":"53","author":"C Rasetti-Escargueil","year":"2009","unstructured":"Rasetti-Escargueil C, Jones RG, Liu Y, Sesardic D (2009) Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon 53:503\u2013511","journal-title":"Toxicon"},{"key":"3094_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1006\/scel.1994.1028","volume":"5","author":"G Schiavo","year":"1994","unstructured":"Schiavo G, Rossetto O, Montecucco C (1994) Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release. Semin Cell Biol 5:221\u2013229","journal-title":"Semin Cell Biol"},{"key":"3094_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/PL00004951","volume":"355","author":"K Wohlfarth","year":"1997","unstructured":"Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355:335\u2013340","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3094_CR30","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.3390\/toxins7124857","volume":"7","author":"S Worbs","year":"2015","unstructured":"Worbs S, Fiebig U, Zeleny R, Schimmel H, Rummel A, Luginbuhl W, Dorner BG (2015) Qualitative and quantitative detection of botulinum neurotoxins from complex matrices: results of the first international proficiency test. Toxins 7:4935\u20134966","journal-title":"Toxins"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03094-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03094-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03094-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:59:29Z","timestamp":1783090769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03094-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3094"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03094-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. PT received honoraria for services provided to Abbott, AbbVie, Boston Scientific, Desitin, Ipsen, Medtronic and Merz. DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Gufic, WizMedi, Shionogi, Desitin, Syntaxin, Allergan-Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of AbbVie and holds patents on botulinum toxin and botulinum toxin therapy. He provides professional consulting services to pharmaceutical companies and professional investment institutions on all aspects of botulinum toxin drugs. He is co-founder and member of the board of directors of Wisper Bio and founder of The Wittgenstein Organisation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}